A Randomized, Double Blind, Three-Arm, Parallel Group, Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US Prolia and EU Prolia by Single-Dose Subcutaneous Injection
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Multiple myeloma; Osteoporosis; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
Most Recent Events
- 26 Oct 2023 New trial record